205 related articles for article (PubMed ID: 513484)
1. Comparison of 1 alpha-hydroxycholecalciferol and 25-hydroxycholecalciferol in the treatment of renal osteodystrophy: greater effect of 25-hydroxycholecalciferol on bone mineralization.
Fournier A; Bordier P; Gueris J; Sebert JL; Marie P; Ferrière C; Bedrossian J; DeLuca HF
Kidney Int; 1979 Feb; 15(2):196-204. PubMed ID: 513484
[No Abstract] [Full Text] [Related]
2. The treatment of renal osteodystrophy with 1-alpha-hydroxycholecalciferol.
Junor BJ; Catto GR; Macleod M
Calcif Tissue Res; 1977 May; 22 Suppl():112-6. PubMed ID: 912512
[No Abstract] [Full Text] [Related]
3. 1alpha-hydroxycholecalciferol and 25-hydroxycholecalciferol in renal bone disease.
Fournier AE; Bordier PJ; Gueris J; Chanard J; Marie P; Ferriere C; Osario M; Bedrossian J; De Luca HF
Calcif Tissue Res; 1976 Aug; 21 Suppl():226-35. PubMed ID: 782662
[No Abstract] [Full Text] [Related]
4. 1alpha-Hydroxycholecalciferol in renal osteodystrophy.
Pierides AM; Ellis HA; Ward MK; Simpson W; Kerr DN
Calcif Tissue Res; 1977 May; 22 Suppl():105-11. PubMed ID: 912511
[No Abstract] [Full Text] [Related]
5. [Long-term effects of a combination of 25-hydroxycholecalciferol and 1-alpha-hydroxycholecalciferol on osteodystrophy in chronic hemodialysis patients].
Sebert JL; Marie A; Kuntz D; Marie P; Gueris J; Smadja A; Fournier A; Quichaud J
Rev Rhum Mal Osteoartic; 1981; 48(7-9):535-41. PubMed ID: 7291931
[TBL] [Abstract][Full Text] [Related]
6. Current status of the use of 1,25(OH)2D3 in the management of renal osteodystrophy.
Massry SG; Goldstein DA; Malluche HH
Kidney Int; 1980 Oct; 18(4):409-18. PubMed ID: 7014981
[No Abstract] [Full Text] [Related]
7. Treatment of renal osteodystrophy with 1alpha-hydroxycholecalciferol (1alpha-OH-D3) in conjunction with a high dialysate calcium.
Winney RJ; Bone JM; Anderson TJ; Robson JS
Calcif Tissue Res; 1977 May; 22 Suppl():94-100. PubMed ID: 912593
[No Abstract] [Full Text] [Related]
8. 1-alpha-hydroxycholecalciferol for renal osteodystrophy.
Brownjohn AM; Goodwin FJ; Hately W; Marsh FP; O'Riordan JL; Papapoulos SE
Br Med J; 1977 Sep; 2(6089):721-3. PubMed ID: 912269
[TBL] [Abstract][Full Text] [Related]
9. Evolution of renal osteodystrophy: correlation of bone histomorphometry and serum mineral and immunoreactive parathyroid hormone values before and after treatment with calcium carbonate or 25-hydroxycholecalciferol.
Bordier PJ; Marie PJ; Arnaud CD
Kidney Int Suppl; 1975 Jan; (2):102-12. PubMed ID: 1057669
[No Abstract] [Full Text] [Related]
10. 1,25-dihydroxycholecalciferol in patients with chronic renal failure.
Henderson RG; Ledingham JG; Norman AW; Oliver DO; Preston C; Russell RG; Small DG; Smith R; Warner GT; Woods CG
Proc Eur Dial Transplant Assoc; 1973; 10(0):202-9. PubMed ID: 4802654
[No Abstract] [Full Text] [Related]
11. 1alpha-Hydroxycholecalciferol in children with renal osteodystrophy.
Postlethwaite RJ; Houston IB
Calcif Tissue Res; 1977 May; 22 Suppl():371-5. PubMed ID: 912549
[No Abstract] [Full Text] [Related]
12. Therapeutic effects of 25-hydroxycholecalciferol and sodium etidronate on renal osteodystrophy.
Zucchelli P; Catizone L; Casanova S; Fabbri L; Fusaroli M
Miner Electrolyte Metab; 1982 Feb; 7(2):86-96. PubMed ID: 6820473
[TBL] [Abstract][Full Text] [Related]
13. [Renal osteodystrophy in two children : a comparison of the effects of 1 alpha-hydroxycholecalciferol (author's transl)].
Chantraine JM; Davin JC; Lambrechts L; Heynen G
Ann Endocrinol (Paris); 1979; 40(2):161-2. PubMed ID: 475307
[TBL] [Abstract][Full Text] [Related]
14. Effects of 1,25-dihydroxycholecalciferol on calcium absorption, muscle weakness, and bone disease in chronic renal failure.
Henderson RG; Russell RG; Ledingham JG; Smith R; Oliver DO; Walton RJ; Small DG; Preston C; Warner GT
Lancet; 1974 Mar; 1(7854):379-84. PubMed ID: 4131033
[No Abstract] [Full Text] [Related]
15. 1 alpha hydroxycholecalciferol and 25 hydroxycholecalciferol in renal bone disease.
Fournier AE; Bordier PJ; Gueris J; Chanard J; Marie P; Ferriere C; Osario M; Bedrossian J; de Luca HF
Proc Eur Dial Transplant Assoc; 1976; 12():227-36. PubMed ID: 935115
[TBL] [Abstract][Full Text] [Related]
16. 1alpha-hydroxychloecalciferol treatment of long-term hemodialyzed patients. Effects on mineral metabolism, bone mineral content and bone morphometry.
Nielsen HE; Melsen F; Christensen MS; Hansen HE; Rodbro P; Johannsen A
Clin Nephrol; 1977 Oct; 8(4):429-34. PubMed ID: 923161
[No Abstract] [Full Text] [Related]
17. Renal osteodystrophy in nondialysed adolescents. Long-term treatment with 1alpha-hydroxycholecalciferol.
Kanis JA; Henderson RG; Heynen G; Ledingham JG; Russell RG; Smith R; Walton RJ
Arch Dis Child; 1977 Jun; 52(6):473-81. PubMed ID: 879833
[TBL] [Abstract][Full Text] [Related]
18. [Immunoreactive parathyroid hormone, 25-hydroxycalciferol and bone histology in renal osteodystrophy (author's transl)].
Offermann G; Schaefer K; Schulz A; Delling G
Klin Wochenschr; 1976 Jul; 54(13):625-32. PubMed ID: 940299
[TBL] [Abstract][Full Text] [Related]
19. 1 alpha-hydroxycholecalciferol in hemodialysis renal osteodystrophy. Adverse effects of anticonvulsant therapy.
Pierides AM; Kerr DN; Ellis HA; Peart KM; O'Riordan JL; DeLuca HF
Clin Nephrol; 1976 Apr; 3(2):189-96. PubMed ID: 819195
[TBL] [Abstract][Full Text] [Related]
20. Symptomatic renal osteodystrophy after renal transplantation: treatment with 1-alpha-hydroxycholecalciferol.
Williams PS; Hillis AN; Carty AJ; Sells RA; Bone JM
Transplant Proc; 1987 Feb; 19(1 Pt 3):2227-8. PubMed ID: 3274500
[No Abstract] [Full Text] [Related]
[Next] [New Search]
